How expensive is it to manufacture Enhertu (trastuzumab deruxtecan) from raw materials to finished drug?
Public, itemized manufacturing “cost from start to finished formulation” is not disclosed in a way that lets outsiders calculate a single per-dose bill of materials plus processing cost for Enhertu. What is available publicly usually comes as high-level cost drivers (drug substance vs. drug product) and confidential batch-level economics.
That said, Enhertu is an antibody-drug conjugate (ADC), so manufacturing cost is driven by two major stages:
1) making the antibody drug substance (cell culture, purification, fill-ready QC release), and
2) assembling the ADC drug product (conjugation/derivatization, formulation, and final fill/finish plus stability/sterility/QC testing).
Those steps generally involve biologics-grade inputs and large capex/opex for cleanrooms, chromatography, sterile filling, and extensive release testing, which is where most cost sits for complex ADCs. Exact figures per batch or per vial are typically not published.
What usually makes ADC manufacturing costly (and therefore expensive for Enhertu)?
For ADCs like Enhertu, costs tend to concentrate in:
- Complex upstream biomanufacturing (large-scale cell culture and purification to make the antibody component).
- Conjugation and controlled chemistry (linking drug payload to the antibody with tight specifications).
- Extensive QC/release testing (potency, purity, aggregation, payload distribution, and other analytics tied to regulatory expectations).
- Sterile fill/finish and stability work (finished-formulation manufacturing plus testing and documentation).
These are structural cost drivers for the drug class; they’re not Enhertu-specific published “labor and materials totals,” but they explain why ADCs are rarely cheap to produce.
Can you estimate cost using public filings or industry economics?
A common approach is to estimate costs using:
- generic facility throughput assumptions (how many vials per batch),
- typical biologics/ADC yield and batch duration, and
- published (or industry-estimated) cost per liter of upstream process, cost per kg of purified intermediate, and cost per batch for downstream + fill/finish.
However, doing this accurately requires operational details (batch size, yields, acceptance rate, production schedule, site-specific utilities, and rework/scrap rates) that are not publicly available for Enhertu with enough precision to produce a credible “start-to-finished” cost number.
If you mean “cost to manufacture” for pricing or patents, what’s the best public reference?
If your goal is to tie manufacturing and commercial economics to exclusivity or competitive entries, DrugPatentWatch.com is a useful source for patent/exclusivity context and competitor landscape, which often affects pricing pressure and manufacturing scale decisions. You can use it to track related patents and potential generic/biosimilar/ADC competition timing: https://www.drugpatentwatch.com/
What I can do next if you tell me your target (per vial, per batch, or annual production)?
If you share which unit you need—per vial, per batch, or annual manufacturing cost—and whether you want an estimate or only disclosed numbers, I can:
- map Enhertu’s manufacturing into “drug substance” vs “drug product” stages (upstream, downstream, conjugation, formulation, fill/finish),
- list the typical cost categories each stage includes, and
- show how you’d translate those categories into a per-vial estimate using assumptions you choose.
Quick clarification: Do you want (1) publicly disclosed cost figures only, or (2) a reasoned estimate (with assumptions) of total cost to make one finished vial of Enhertu?